Chemical Leptin ELISA Kit

Recommended Leptin Product (geliefert von: Anmelden zum Anzeigen )

Leptin (LEP) ELISA Kits
  • ob
  • obese
  • LEPD
  • OB
  • OBS
  • leptin
  • Lep
  • LEP
  • lep
Kits mit alternativen Reaktivitäten:
Sandwich ELISA
0-100 ng/mL
Untere Nachweisgrenze
0 ng/mL
Anmelden zum Anzeigen
Hersteller Produkt- Nr.
Anmelden zum Anzeigen

Produkt kostenlos erhalten?

Für Ihre Validierungsdaten erstatten wir Ihnen den vollen Kaufpreis. Ich möchte dieses Produkt validieren

Mehr erfahren

Produktnummer ABIN997071
$ 818.71
Zzgl. Versandkosten $45.00


Antigen Leptin (LEP) ELISA Kits
Reaktivität Chemical
Kits mit alternativen Reaktivitäten:
(61), (39), (30), (20), (14), (13), (12), (9), (7), (6), (5), (5), (4), (2), (1), (1)
Methodentyp Sandwich ELISA
Detektionsbereich 0-100 ng/mL
Untere Nachweisgrenze 0 ng/mL
Applikation ELISA
Pubmed 3 Publikationen vorhanden
Hersteller Anmelden zum Anzeigen

Produktdetails Leptin ELISA Kit

Antigendetails Anwendungsinformationen Handhabung Referenzen für Leptin Kit (ABIN997071) Bilder
Verwendungszweck The DAI Leptin Enzyme Immunoassay Kit provides materials for the quantitative determination of Leptin in serum and plasma.
Proben Serum
Nachweismethode Colorimetric
Analytische Methode Quantitative
Sensitivität 0.3 ng/mL


Produktdetails Leptin ELISA Kit Anwendungsinformationen Handhabung Referenzen für Leptin Kit (ABIN997071) Bilder zurück nach oben
Andere Bezeichnung Leptin (LEP ELISA Kit Abstract)
Forschungsgebiet Cardiovascular, Atherosclerosis, Hormones
Pathways JAK-STAT Signalweg, AMPK Signaling, Hormone Transport, Peptide Hormone Metabolism, Hormone Activity, Negative Regulation of Hormone Secretion, Regulation of Carbohydrate Metabolic Process, Feeding Behaviour, Monocarboxylic Acid Catabolic Process


Produktdetails Leptin ELISA Kit Antigendetails Handhabung Referenzen für Leptin Kit (ABIN997071) Bilder zurück nach oben

Limitations of procedure:
1. Interfering Substances Any improper handling of samples or modification of this test might influence the results.
2. Drug Interferences Until today no substances (drugs) are known - us, which have an influence - the measurement of Leptin in a sample.

Legal Aspects
1. Reliability of Results The test must be performed exactly as per the manufacturer's instructions for use. Moreover the user must strictly adhere - the rules of GLP (Good Laboratory Practice) or other applicable national standards and/or laws. This is especially relevant for the use of control reagents. It is important - always include, within the test procedure, a sufficient number of controls for validating the accuracy and precision of the test. The test results are valid only if all controls are within the specified ranges and if all other test parameters are also within the given assay specifications. In case of any doubt or concern please contact DAI.
2. Therapeutical Consequences Therapeutical consequences should never be based on laboratory results alone even if all test results are in agreement with the items as stated under point 10.1. Any laboratory result is only a part of the total clinical picture of a patient. Only in cases where the laboratory results are in acceptable agreement with the overall clinical picture of the patient should therapeutical consequences be derived. The test result itself should never be the sole determinant for deriving any therapeutical consequences.
3. Liability Any modification of the test kit and/or exchange or mixture of any components of different lots from one test kit - another could negatively affect the intended results and validity of the overall test. Such modification and/or exchanges invalidate any claim for replacement. Claims submitted due - customer misinterpretation of laboratory results subject - point 10.2. are also invalid. Regardless, in the event of any claim, the manufacturer's liability is not - exceed the value of the test kit. Any damage caused - the test kit during transportation is not subject - the liability of the manufacturer.

Probenmenge 15 μL
Testdauer 1 h
Plattentyp Pre-coated
Testdurchführung General Remarks
1. All reagents and specimens must be allowed to come to room temperature before use. All reagents must be mixed without foaming.
2. Once the test has been started, all steps should be completed without interruption.
3. Use new disposal plastic pipette tips for each standard, control or sample in order to avoid cross contamination
4. Absorbance is a function of the incubation time and temperature. Before starting the assay, it is recommended that all reagents are ready, caps removed, all needed wells secured in holder, etc. This will ensure equal elapsed time for each pipetting step without interruption.
5. As a general rule the enzymatic reaction is linearly proportional to time and temperature.
Ergebnisberechnung It is strongly recommended that each laboratory should determine its own normal and abnormal values. In a study conducted with apparently normal healthy adults, using the DAI Leptin ELISA the following values are observed: Population ng/mL Males
3.84 ±
1.79 Females 7.36 ±

1.Assay Dynamic Range The range of the assay is between 0 - 100 ng/mL.
2.Specificity of Antibodies (Cross Reactivity) The following substances were tested for cross reactivity of the assay: Component Cross reactivity Human Leptin 100 % Rat Leptin <0.2 % Mouse Leptin <0.2 % Human Insulin N.D. Human Proinsulin N.D. Rat Insulin N.D. Human C-Peptide N.D. Glucagon N.D. IGF-I N.D. N.D.: Not detectable
3. Analytical
Beschränkungen Nur für Forschungszwecke einsetzbar


Produktdetails Leptin ELISA Kit Antigendetails Anwendungsinformationen Referenzen für Leptin Kit (ABIN997071) Bilder zurück nach oben
Lagerung 4 °C
Haltbarkeit 12-14 months

Referenzen für Leptin Kit (ABIN997071)

Produktdetails Leptin ELISA Kit Antigendetails Anwendungsinformationen Handhabung Bilder zurück nach oben
Allgemeine Veröffentlichungen

Klosz: "Quality management for the processing of medical devices." in: GMS Krankenhaushygiene interdisziplinär, Vol. 3, Issue 3, pp. Doc22, 2010

Guilloume, Björntorp: "Obesity in children. Environmental and genetic aspects." in: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme, Vol. 28, Issue 11, pp. 573-81, 1997

Considine, Sinha, Heiman, Kriauciunas, Stephens, Nyce, Ohannesian, Marco, McKee, Bauer: "Serum immunoreactive-leptin concentrations in normal-weight and obese humans." in: The New England journal of medicine, Vol. 334, Issue 5, pp. 292-5, 1996